ReviewJournal of clinical medicine2020
The Immune Microenvironment in Penile Cancer and Rationale for Immunotherapy.
Review in Journal of clinical medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 41 citations in OpenAlex.
- CD47 as a prognostic biomarker and potential immunotherapy target in penile squamous cell carcinoma.Scientific reports · 2026Article
- Immune checkpoint inhibitor therapy for advanced HPV-related penile squamous cell carcinoma: a rare case report.Frontiers in oncology · 2025Article
- The role of immunotherapy in targeting tumor microenvironment in genitourinary cancers.Frontiers in immunology · 2025Review
- Role of PD-1/PD-L1 signaling axis in oncogenesis and its targeting by bioactive natural compounds for cancer immunotherapy.Military Medical Research · 2024Review
- Hypomethylation at H19DMR in penile squamous cell carcinoma is not related to HPV infection.Epigenetics · 2024Article
- Gene Expression Profiling of the Peritumoral Immune Cell Infiltrate of Penile Squamous Cell Carcinomas.International journal of molecular sciences · 2024Article
- Multiplex Immunofluorescence Captures Progressive Immune Exhaustion with Advancing Penile Squamous Cell Cancer Stage.Cancers · 2024Article
- Advances in molecular basis of response to immunotherapy for penile cancer: better screening of responders.Frontiers in oncology · 2024Review
- Conversion therapy for advanced penile cancer with tislelizumab combined with chemotherapy: A case report and review of literature.World journal of clinical cases · 2022Article
- Penile cancer: Updates in systemic therapy.Asian journal of urology · 2022Review
- Tumor-associated immune cell infiltrate density in penile squamous cell carcinomas.Virchows Archiv : an international journal of pathology · 2022Article
- BIRC5 regulates inflammatory tumor microenvironment-induced aggravation of penile cancer development in vitro and in vivo.BMC cancer · 2022Article
- 5-methylcytosine RNA methylation regulators affect prognosis and tumor microenvironment in lung adenocarcinoma.Annals of translational medicine · 2022Article
- The peri- and intratumoral immune cell infiltrate and PD-L1 status in invasive squamous cell carcinomas of the penis.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2022Article
- Interplay Between Immune and Cancer-Associated Fibroblasts: A Path to Target Metalloproteinases in Penile Cancer.Frontiers in oncology · 2022Article
- National trends and survival outcomes of penile squamous cell carcinoma based on human papillomavirus status.Cancer medicine · 2021Article
- Pembrolizumab as a promising intervention for advanced penile cancer.International braz j urol : official journal of the Brazilian Society of UrologyArticle
- High quality palliative alternative for patients with advanced locoregional (CN3 Stage) penile cancer.International braz j urol : official journal of the Brazilian Society of UrologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Penile cancer is an extremely rare malignancy that accounts for approximately 1% of cancer deaths in the United States every year. While primary penile cancer can be managed surgically, advanced and metastatic forms of the disease require more aggressive management plans with systemic chemotherapy and/or radiotherapy. Despite the meaningful response to systemic treatments, the 2-year progression-free survival and disease-specific survival have shown disappointing results. Therefore, there is a crucial need for alternative treatment options with more favorable outcomes and a lower toxicity profile. There are currently extensive studies of tumor molecular biology and clinical trials with targeted molecular therapies, such as PD-1, PD-L1, and CTLA-4. In this review, we will describe the penile cancer microenvironment, and summarize the rationale for immunotherapy in penile cancer patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.